Humacyte is trading 5.82% up at $0.37 after the October 14 regular-session close of $0.35; no clear company-specific after-hours catalyst was identified.
- The company’s Phase 3 V012 presentation announcement was issued October 12, not October 14.
- September CPI came in hotter than expected, and reports linked inflation concerns to equity declines. Humacyte’s after-hours move was upward, so this does not clearly explain its direction.